Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene
Links shared publicly online about this topic.
- 43total visits
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene
View full resource at medicalnewstoday.com
Tags: Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Lung, Genes, FDA
Most Recently Shared on August 27, 2011 at 6:01 am By:
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene: The US FDA has approved Xalkori ... http://t.co/UQkBTuN
Also Shared By:
Pfizer, Abbott receive FDA approval for Xalkori, Vysis ALK FISH test to treat NSCLC
news-medical.net — “The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene.” View full resource at news-medical.net
Most Recently Shared on August 29, 2011 at 7:21 am By:
Pfizer, Abbott receive FDA approval for Xalkori, Vysis ALK FISH test to treat NSCLC: The U.S. Food and Drug Admi... http://t.co/6umNI8D
FDA Approves Xalkori With Companion Diagnostic For A Type Of Late-stage Lung Cancer - QualityPoint Technologies
qualitypointtech.net — “The U.S. Food and Drug Administration approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene. Xalkori is being approved with a companion diagnostic test that will help determine if a patient has the abnormal ALK gene, a first-of-a-kind genetic test called the Vysis ALK Break Apart FISH Probe Kit. It is the second such targeted therapy approved by t” View full resource at qualitypointtech.net
Most Recently Shared on August 27, 2011 at 12:00 pm By:
FDA Approves Xalkori With Companion Diagnostic For A Type Of Late-stage Lung Cancer: The U.S. Food and Drug Admini... http://t.co/6HRx8I6
FDA Approves Xalkori With Companion Diagnostic For A Type Of Late-stage Lung Cancer - QualityPoint Technologies
qualitypointtech.net — “The U.S. Food and Drug Administration approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene. Xalkori is being approved with a companion diagnostic test that will help determine if a patient has the abnormal ALK gene, a first-of-a-kind genetic test called the Vysis ALK Break Apart FISH Probe Kit. It is the second such targeted therapy approved by t” View full resource at qualitypointtech.net
Most Recently Shared on August 27, 2011 at 9:45 am By:
FDA Approves Xalkori With Companion Diagnostic For A Type Of Late-stage Lung Cancer: The U.S. Food and Drug Admini... http://t.co/Dab3lox
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene - QualityPoint Technologies
qualitypointtech.net — “The US FDA has approved Xalkori (crizotinib) for the treatment of late-stage NSCLC (non-small cell lung cancer) in patients who have the abnormal ALK (anaplastic lymphoma kinase) gene. Patients undergo a genetic test, known as the Vysis ALK Break Apart FISH Probe Kit which detects the abnormal gene. The FDA has also approved this test. The abnormal ALK gene causes cancer to develop and grow. Approximately 1% to 7% of patients with non-small cell lung cancer have this genetic abnormality. They ar” View full resource at qualitypointtech.net
Most Recently Shared on August 27, 2011 at 4:45 am By:
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene: The US FDA has approved Xalkori (c... http://t.co/IX8ESfO
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene - QualityPoint Technologies
qualitypointtech.net — “The US FDA has approved Xalkori (crizotinib) for the treatment of late-stage NSCLC (non-small cell lung cancer) in patients who have the abnormal ALK (anaplastic lymphoma kinase) gene. Patients undergo a genetic test, known as the Vysis ALK Break Apart FISH Probe Kit which detects the abnormal gene. The FDA has also approved this test. The abnormal ALK gene causes cancer to develop and grow. Approximately 1% to 7% of patients with non-small cell lung cancer have this genetic abnormality. They ar” View full resource at qualitypointtech.net
Most Recently Shared on August 27, 2011 at 1:45 am By:
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene: The US FDA has approved Xalkori (c... http://t.co/M9EhGbr
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene
medicalnewstoday.com — “The US FDA has approved Xalkori (crizotinib) for the treatment of late-stage NSCLC (non-small cell lung cancer) in patients who have the abnormal ALK (anaplastic lymphoma kinase) gene. Patients un” View full resource at medicalnewstoday.com
Most Recently Shared on August 27, 2011 at 12:05 am By:
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene http://mnt.to/3Zf5 #healthnews
Advertisement
Lungs and Breathing
@Lung_Breathing
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene: The US FDA has approved Xalkori ... http://t.co/L1Il8lh
1 year ago...